{"id":50972,"date":"2025-12-16T22:06:33","date_gmt":"2025-12-16T14:06:33","guid":{"rendered":"https:\/\/flcube.com\/?p=50972"},"modified":"2025-12-16T22:06:34","modified_gmt":"2025-12-16T14:06:34","slug":"ubrigene-partners-with-circurna-on-circrna-manufacturing-for-global-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50972","title":{"rendered":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials"},"content":{"rendered":"\n<p><strong>uBriGene Biosciences International Co.<\/strong> announced a strategic partnership with <strong>Circurna<\/strong>, a biotechnology company developing next\u2011generation <strong>circular RNA (circRNA) therapeutics<\/strong>. Under the agreement, uBriGene will provide <strong>end\u2011to\u2011end services<\/strong> for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnership Scope<\/strong><\/td><td>End\u2011to\u2011end CMC services for circRNA DS\/DP<\/td><\/tr><tr><td><strong>uBriGene Services<\/strong><\/td><td>Process development, analytical methods, scaled manufacturing, GMP delivery<\/td><\/tr><tr><td><strong>Circurna Platform<\/strong><\/td><td>Programmable circularization, advanced RNA engineering, targeted delivery<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Accelerate R&amp;D pipeline to First\u2011in\u2011Human (FIH) trials; build scalable CMC system<\/td><\/tr><tr><td><strong>Leverage<\/strong><\/td><td>uBriGene\u2019s global manufacturing network and cross\u2011regional regulatory expertise<\/td><\/tr><tr><td><strong>Quality &amp; Compliance<\/strong><\/td><td>Robust quality system, process reproducibility, multi\u2011country submission readiness<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform<\/th><th>Application<\/th><\/tr><\/thead><tbody><tr><td><strong>Circurna<\/strong><\/td><td>Proprietary circRNA technology<\/td><td>Next\u2011gen RNA therapeutics for unaddressed diseases<\/td><\/tr><tr><td><strong>uBriGene<\/strong><\/td><td>Global manufacturing &amp; regulatory network<\/td><td>Ensures GMP compliance and global development support<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Circurna:<\/strong> Partnership provides <strong>immediate CMC capabilities<\/strong> without capital investment; leverages uBriGene\u2019s <strong>regulatory experience<\/strong> to navigate US, EU, and China submissions; accelerates <strong>FIH trial readiness<\/strong> for novel circRNA pipeline.<\/li>\n\n\n\n<li><strong>For uBriGene:<\/strong> Secures <strong>anchor client<\/strong> in emerging circRNA space; expands service portfolio into <strong>next\u2011generation RNA modalities<\/strong>; demonstrates ability to support <strong>global biotechs<\/strong> from early\u2011stage to commercialization.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> circRNA therapeutics projected to capture <strong>$5\u20118\u202fbillion<\/strong> by 2035; partnerships between <strong>platform companies<\/strong> and <strong>CDMOs<\/strong> are critical to overcome manufacturing bottlenecks and enable rapid translation.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership\u2019s ability to advance Circurna\u2019s pipeline to FIH trials, manufacturing scalability, and market potential for circRNA therapeutics. Actual results may differ due to technical risks, regulatory delays, or competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50976,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4507,1285],"class_list":["post-50972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-circurna","tag-ubrigene-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50972\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials\" \/>\n<meta property=\"og:description\" content=\"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50972\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-16T14:06:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T14:06:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials\",\"datePublished\":\"2025-12-16T14:06:33+00:00\",\"dateModified\":\"2025-12-16T14:06:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972\"},\"wordCount\":297,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1603.webp\",\"keywords\":[\"Circurna\",\"uBriGene Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50972#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50972\",\"name\":\"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1603.webp\",\"datePublished\":\"2025-12-16T14:06:33+00:00\",\"dateModified\":\"2025-12-16T14:06:34+00:00\",\"description\":\"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50972\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50972#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials - Insight, China&#039;s Pharmaceutical Industry","description":"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50972","og_locale":"en_US","og_type":"article","og_title":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials","og_description":"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.","og_url":"https:\/\/flcube.com\/?p=50972","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-16T14:06:33+00:00","article_modified_time":"2025-12-16T14:06:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50972#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50972"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials","datePublished":"2025-12-16T14:06:33+00:00","dateModified":"2025-12-16T14:06:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50972"},"wordCount":297,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50972#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","keywords":["Circurna","uBriGene Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50972#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50972","url":"https:\/\/flcube.com\/?p=50972","name":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50972#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50972#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","datePublished":"2025-12-16T14:06:33+00:00","dateModified":"2025-12-16T14:06:34+00:00","description":"uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next\u2011generation circular RNA (circRNA) therapeutics. Under the agreement, uBriGene will provide end\u2011to\u2011end services for circRNA drug substance (DS) and drug product (DP), including process and analytical method development, scaled\u2011up manufacturing, and GMP\u2011grade delivery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50972#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50972"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50972#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","width":1080,"height":608,"caption":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50972#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50972"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50972\/revisions"}],"predecessor-version":[{"id":50977,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50972\/revisions\/50977"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50976"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}